HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans

HIF2α is a key driver of kidney cancer. Using a belzutifan analogue (PT2399), we previously showed in tumorgrafts (TG) that ∼50% of clear cell renal cell carcinomas (ccRCC) are HIF2α dependent. However, prolonged treatment induced resistance mutations, which we also identified in humans. Here, we ev...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical cancer research Ročník 28; číslo 24; s. 5405
Hlavní autoři:	Ma, Yuanqing, Joyce, Allison, Brandenburg, Olivia, Saatchi, Faeze, Stevens, Christina, Toffessi Tcheuyap, Vanina, Christie, Alana, Do, Quyen N, Fatunde, Oluwatomilade, Macchiaroli, Alyssa, Wong, So C, Woolford, Layton, Yousuf, Qurratulain, Miyata, Jeffrey, Carrillo, Deyssy, Onabolu, Oreoluwa, McKenzie, Tiffani, Mishra, Akhilesh, Hardy, Tanner, He, Wei, Li, Daniel, Ivanishev, Alexander, Zhang, Qing, Pedrosa, Ivan, Kapur, Payal, Schluep, Thomas, Kanner, Steven B, Hamilton, James, Brugarolas, James
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.12.2022
Témata:	Animals Basic Helix-Loop-Helix Transcription Factors - metabolism Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology Cell Line, Tumor Clinical Trials, Phase I as Topic Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - pathology Mice Polycythemia RNA, Small Interfering - genetics
ISSN:	1557-3265, 1557-3265
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!